A retrospective two-years' review was conducted in 95 patients (146 impaired ears) who considered to have steroid unresponsive autoimmune inner ear disease (AIED) and on all patients positive for antibody for a 68kDa bovine inner ear antigen. Pure tone average (PTA) at 250Hz, 500Hz, 1 kHz, 2 kHz and 4 kHz was used as objective measure of outcome. The patients were treated with cyclophosphamide (CPM).
At the initial treatment, 73 of 146 impaired ears (50%) exhibited a positive response to therapy. 41patients (64 impaired ears) treated with CPM had recurrence hearing loss. Positive response to CPM therapy at the end of study was seen in 46% of patients and was not significantly different as compared with the reaction of the initial CPM treatment. However, 16% of impaired ears with recurrence hearing loss were worsened. The PTA of the patients demonstrated with those normal recoveries and marked recovery was significantly low level as compared with those of patients who resulted in better, stable and worsened hearing.
In recovery rate by disease type, acute low tone sensory neural hearing loss was 69% and followed by 55% of Meniere's disease, 49% of sudden deafness, 25% of contralateral endolymphatic hydrops and 22% of idiopathic sensory neural hearing loss. 31 patients with rotatory vertigo attack were significantly recovered.
No significant difference in the improvement of hearing loss was seen between patients with or without vertigo.
In conclusion, intermittent low dose of CPM therapy to patients with steroid unresponsive AIED showed in 46% improvement rate of hearing loss, though 41patients (64 impaired ears) had reactivated in two years.
View full abstract